CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related hospitalization and 76-96% against COVID-associated death. Despite the shift away ...

With vaccine revenue crumbling and layoffs in full swing, is Moderna’s slimmed-down strategy a smart move or a red flag for ...

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Moderna Inc. is cutting about 10% of its workforce, part of an effort by the struggling biotech company to reduce spending as ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by ...

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the ...

Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...

Moderna announced Monday that its COVID-19 vaccine booster increases antibody levels against the omicron variant within a month of getting the shot. In a lab study, the company gave 20 fully ...